This is the "Home" page of the "Grand Rounds 03/01/17 @ BID-Needham: Dr. Marwa Sabe" guide.
Alternate Page for Screenreader Users
Skip to Page Navigation
Skip to Page Content

Grand Rounds 03/01/17 @ BID-Needham: Dr. Marwa Sabe  

Pulmonary Hypertension in Left Heart Disease
Last Updated: Mar 6, 2017 URL: http://bidmc.libguides.com/Sabe/2017 Print Guide RSS Updates
Home Print Page
  Search: 
 

Speaker: Date: Topic

Marwa Sabe, MD, MPH

Mar. 1, 2016

Pulmonary Hypertension in Left Heart Disease

      

    Responsibility for Content

    The PowerPoint presentation, Take-Away points, Objectives, and Abstract links were sent by Medical Library Services and the CME Committee.

    Diane E. Young, Information Specialist

    dyoung3@bidmc.harvard.edu

     

        
       

      Feedback Welcome

      Was this information helpful?

      How useful is this page?
      (1 = Not Useful, 5 = Very Useful!)

      Additional comments:


      Your Email:


      Take-Away Points of the Presentation

      1. PH due to left heart disease (WHO Group II PH) is the most common cause of PH.

      2. PH in LHD is associated with poor outcomes.

      3. PH in LHD can be passive or reactive and may be reversible or fixed.

      4. Treatment relies mostly on treating the underlying cause of left heart disease.

      5. PDE 5 inhibitors and soluble guanylate cyclase activators are safe in these patients and are being investigated for efficacy.

      6. PDE 5 inhibitors should be considered in the pre-transplant and post LVAD population.

          

        Objectives of the Presentation

        Participants should be able to:

        • Define and classify types of pulmonary hypertension and specifically Group II PH.
        • Understand the pathophysiology of Group II PH.
        • Distinguish pre and post capillary pulmonary hypertension.
        • Understand the diagnostic approach for Group II PH.
        • Become familiar with different treatment pathways in pulmonary hypertension and specifically for Group II PH.
        • Understand how pulmonary hypertension affects advanced heart failure evaluation and therapies.
            
           

          PDF of the PowerPoint Presentation

          Disclosures

          Director of Medical Education and Committee Member have indicated they have no relevant financial interests or relationships to disclose. Faculty has indicated no relevant financial interests or relationships to disclose.

              

            THIS SITE IS MAINTAINED BY KNOWLEDGE SERVICES AT THE BETH ISRAEL DEACONESS MEDICAL CENTER.
            CLICK HERE TO ASK A QUESTION OR REPORT A PROBLEM.

            Description

            Loading  Loading...

            Tip